Bristol-Myers Squibb and Simcere Pharmaceutical Group expand partnership to develop cardiovascular drug

Bristol-Myers Squibb and Simcere Pharmaceutical Group, a leading pharmaceutical company in China, have announced the expansion of their year-old partnership. Both companies have agreed to co-develop the cardiovascular disease preventing drug BMS-795311.  With the collective strength of the two companies, the collaboration has set expectations to accelerate clinical Phase 2a proof-of-concept delivery. The terms of agreement state Simcere has rights to commercialize and develop BMS-795311 in China, while  Bristol-Myers Squibb will obtain the same rights in the rest of the global market. The financial details were not made readily available.

 

SOURCE: Bristol-Myers Squibb Press Release